Status:
ACTIVE_NOT_RECRUITING
Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients
Lead Sponsor:
Royal Marsden NHS Foundation Trust
Collaborating Sponsors:
Janssen, LP
Conditions:
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Eligibility:
MALE
18+ years
Brief Summary
The ADAPT study is an observational study of apalutamide, which can be given to patients with hormone sensitive metastatic prostate cancer as standard of care. The clinical decision for patients to ha...
Eligibility Criteria
Inclusion
- Male 18 years of age or older
- Histologically confirmed diagnosis of adenocarcinoma of the prostate with both:
- Metastatic hormone sensitive prostate cancer
- Treatment decision for apalutamide by clinician
Exclusion
- Non-metastatic prostate cancer
- Prior chemotherapy / abiraterone / apalutamide / darolutamide / enzalutamide for prostate cancer
- Unable to complete patient reported outcome questionnaires
Key Trial Info
Start Date :
September 26 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2027
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT06019676
Start Date
September 26 2023
End Date
April 1 2027
Last Update
September 18 2025
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
The Royal Marsden Hospital
Sutton, Surrey, United Kingdom, SM2 5PT
2
Buckinghamshire Healthcare NHS Trust
Aylesbury, United Kingdom, HP21 8AL
3
Northern Ireland Cancer Centre, Belfast Health & Social Care Trust
Belfast, United Kingdom, BT9 7AB
4
East Lancashire Hospitals NHS Trust
Blackburn, United Kingdom, BB2 3HH